Recipharm’s $11.4 Million Investment in Nichepharm Lifesciences


Khaitan & Co advised Nichepharm Lifesciences Private Limited and the Sobti Family in the transaction.

Recipharm has entered a partnership with Sobti to create production capacity in India for a range of sterile dosage forms.

The Sobti family’s newly created company, Nichepharm Lifesciences Pvt Ltd. will initially issue an 8% equity stake to Recipharm for an investment of approximately $11.4 million.

Recipharm will have the option to acquire an additional 16% share during 2021.

The new facility that will be established in Dehradun, Uttarakhand in northern India is expected to be fully operational by 2022 and to be approved by the European Commission and other international regulatory agencies.

Khaitan & Co advised Nichepharm Lifesciences Private Limited and the Sobti Family with a team including Kalpana Unadkat (Picture), Purti Minawala and Amiya Kumar Pati.

Involved fees earner: Kalpana Unadkat – Khaitan & Co.;

Law Firms: Khaitan & Co.;

Clients: Nichepharm Lifesciences;